Fabrication Method of PEG–KGM/Agar Carbon-Based Bioscaffold
ONYXCELL offers a safer and more cost-effective alternative to traditional 3D cell culture matrices such as Matrigel, which is derived from mouse sarcoma tumors and carries risks of uncontrolled proliferation. Unlike expensive human tissue-derived matrices, ONYXCELL uses processed human hair byproducts to create a conductive, high-porosity bioscaffold that enhances stem cell growth at a lower price point. Its scalability, human-based source, and improved 3D microenvironment position it as a more sustainable and commercially viable solution for accelerating stem cell expansion.
Stem cell treatments and research are limited by insufficient cell supply, high processing costs, technical complexity, and long culture times. Extracting stem cells from sources such as umbilical cords or bone marrow often results in low-quality and low-quantity yields. Maintaining cell cultures requires expensive facilities and resources, costing up to $5,000 monthly, while slow proliferation delays treatments and reduces effectiveness. As demand for regenerative medicine grows, there is a pressing need for a faster, cost-effective, and scalable method to expand high-quality stem cells.
ONYXCELL has developed a carbon-based biological bioscaffold derived from human hair through a two-stage pyrolysis and fabrication process. The bioscaffold creates a conductive and highly porous three-dimensional microenvironment that enhances stem cell attachment, viability, and rapid proliferation. The scaffold can be provided in solid or liquid form and is integrated into culture plates or solutions, allowing stem cells to grow more efficiently and at a larger scale. This improved 3D microenvironment accelerates cell expansion while maintaining safety and integrity for therapeutic applications.
The innovation lies in a carbon-based bioscaffold derived from human hair that enhances stem cell growth in a conductive, porous 3D environment. It improves cell yield, speed, and scalability while reducing cost and complexity, enabling more efficient and reproducible large-scale production for regenerative medicine.
